Inactive Instrument

GOLD SWAP Stock price OTC Bulletin Board

Equities

GDSW

US38074W1009

Pharmaceuticals

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for GOLD SWAP
Sales 2024 * 72K Sales 2025 * 72K Capitalization 5.54M
Net income 2024 * -4M Net income 2025 * -8M EV / Sales 2024 * 77 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 77 x
P/E ratio 2024 *
-3.48 x
P/E ratio 2025 *
-2.79 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.26%
More Fundamentals * Assessed data
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic CI
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain CI
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery CI
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology CI
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024. CI
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD CI
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment MT
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia CI
Top Premarket Decliners MT
Top Premarket Decliners MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023. CI
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 10-07-12
Director of Finance/CFO 59 22-09-26
Chief Tech/Sci/R&D Officer 58 22-08-31
Members of the board TitleAgeSince
Chief Executive Officer 54 10-07-12
Director/Board Member 67 20-01-15
Director/Board Member 46 20-09-30
More insiders
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
More about the company
  1. Stock
  2. Equities
  3. Stock Silo Pharma, Inc.
  4. Stock GOLD SWAP - OTC Bulletin Board